Arbor Biotechnologies Doses First Patient in ABO-101 Gene Editing Study
Arbor Biotechnologies has dosed the first patient in its Phase 1/2 rephine trial of ABO-101, a CRISPR gene editing...
Tenaya Gene Therapies Advance to Clinical Trials Following Positive Safety Reviews
Tenaya Therapeutics announced positive recommendations from independent Data Safety Monitoring Boards (DSMBs) for its two cardiovascular gene therapy trials:...
New Amsterdam Pharma’s Broadway Trial Shows Positive Alzheimer’s Biomarker Reductions
NewAmsterdam Pharma’s cholesteryl ester transfer protein (CETP) inhibitor, obicetrapib, significantly reduced plasma p-tau217 levels, a key Alzheimer’s disease biomarker,...
Vyne Announces Mixed Phase 2b Results for Repibresib Gel in Vitiligo
VYNE Therapeutics’ Phase 2b trial of Repibresib gel for nonsegmental vitiligo failed to meet its primary endpoint of F-VASI50...
Cortec Achieves German BCI Milestone: First Human Brain Implant
CorTec GmbH has implanted its Brain Interchange™ brain-computer interface (BCI) system in a human for the first time. The...
Therini Doses First Patient in Alzheimer’s Trial
Therini Bio has dosed the first patient in a Phase 1b trial of THN391, a monoclonal antibody targeting the...
Vivex Completes Subject Enrollment for Ascend Trial of Via Disc NP
Vivex Biologics has completed enrollment in its ASCEND trial of VIA Disc NP for symptomatic degenerative disc disease (DDD)....
EyePoint Completes Duravyu™ Phase 3 Wet AMD Trial Enrollment
EyePoint Pharmaceuticals has completed enrollment in its Phase 3 LUCIA trial of DURAVYU (vorolanib intravitreal insert) for wet age-related...
Pharmazz Inc. Begins Phase 3 Sovateltide Trial for Stroke
Pharmazz has initiated its pivotal Phase 3 RESPECT-ETB trial evaluating sovateltide, a first-in-class endothelin-B receptor agonist, in acute cerebral...
Fulcrum Therapeutics Announces Results from Phase 1b Pioneer Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics reported positive 12-week data from the 12mg dose cohort of its Phase 1b PIONEER trial of pociredir...